JP7863957B2 - 新規な人工核酸分子 - Google Patents
新規な人工核酸分子Info
- Publication number
- JP7863957B2 JP7863957B2 JP2020521986A JP2020521986A JP7863957B2 JP 7863957 B2 JP7863957 B2 JP 7863957B2 JP 2020521986 A JP2020521986 A JP 2020521986A JP 2020521986 A JP2020521986 A JP 2020521986A JP 7863957 B2 JP7863957 B2 JP 7863957B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- utr
- artificial nucleic
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189376A JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
| JP2026021312A JP2026090405A (ja) | 2017-10-19 | 2026-02-12 | 新規な人工核酸分子 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017076775 | 2017-10-19 | ||
| EPPCT/EP2017/076741 | 2017-10-19 | ||
| EP2017076741 | 2017-10-19 | ||
| EPPCT/EP2017/076775 | 2017-10-19 | ||
| PCT/EP2018/057552 WO2018172556A1 (en) | 2017-03-24 | 2018-03-23 | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EPPCT/EP2018/057552 | 2018-03-23 | ||
| EPPCT/EP2018/076185 | 2018-09-26 | ||
| EP2018076185 | 2018-09-26 | ||
| PCT/EP2018/078453 WO2019077001A1 (en) | 2017-10-19 | 2018-10-17 | NEW ARTIFICIAL NUCLEIC ACID MOLECULES |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189376A Division JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2026021312A Division JP2026090405A (ja) | 2017-10-19 | 2026-02-12 | 新規な人工核酸分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501572A JP2021501572A (ja) | 2021-01-21 |
| JP2021501572A5 JP2021501572A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JP7863957B2 true JP7863957B2 (ja) | 2026-05-22 |
Family
ID=66173912
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521986A Active JP7863957B2 (ja) | 2017-10-19 | 2018-10-17 | 新規な人工核酸分子 |
| JP2023189376A Pending JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A Pending JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
| JP2026021312A Pending JP2026090405A (ja) | 2017-10-19 | 2026-02-12 | 新規な人工核酸分子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189376A Pending JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A Pending JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
| JP2026021312A Pending JP2026090405A (ja) | 2017-10-19 | 2026-02-12 | 新規な人工核酸分子 |
Country Status (13)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Cpf1に基づくゲノム編集の治療適用 |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| EP3773702A2 (en) * | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| CA3102135A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除 |
| CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| EP4007814A1 (en) * | 2019-07-26 | 2022-06-08 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
| JP2022546417A (ja) * | 2019-08-29 | 2022-11-04 | チューリッヒ大学 | 最小mRNAおよびその使用 |
| AU2020371697A1 (en) * | 2019-10-22 | 2022-05-26 | Genevant Sciences Gmbh | Ornithine transcarbamylase (OTC) constructs and methods of using the same |
| CN110592223B (zh) * | 2019-10-31 | 2022-10-25 | 中南大学湘雅三医院 | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 |
| CN112759652B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种嵌合抗原受体及其应用 |
| US12606822B2 (en) * | 2019-11-07 | 2026-04-21 | Icahn School Of Medicine At Mount Sinai | Synthetic modified RNA and uses thereof |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CA3162019A1 (en) | 2019-12-20 | 2021-06-24 | Gemma NAVARRO | Lipid nanoparticles for delivery of nucleic acids |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| DE202021004130U1 (de) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US20230096704A1 (en) * | 2020-02-05 | 2023-03-30 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| AU2021247163A1 (en) * | 2020-04-01 | 2022-10-20 | University Of Florida Research Foundation, Incorporated | Multilamellar RNA nanoparticle vaccine against SARS-CoV-2 |
| CN111413498B (zh) * | 2020-04-08 | 2023-08-04 | 复旦大学附属中山医院 | 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用 |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| US20220017971A1 (en) * | 2020-07-15 | 2022-01-20 | Kookmin University Industry Academy Cooperation Foundation | Composition for predicting chemotherapy resistance of ovarian cancer and use thereof |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| WO2022028559A1 (en) * | 2020-08-07 | 2022-02-10 | The Hong Kong University Of Science And Technology | Compositions and methods for increasing protein expression |
| CN116635525A (zh) * | 2020-08-21 | 2023-08-22 | 北京大学 | 环状rna疫苗及其使用方法 |
| WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
| WO2022076901A1 (en) * | 2020-10-09 | 2022-04-14 | Duke University | Novel targets for reactivation of prader-willi syndrome-associated genes |
| CN112280750B (zh) * | 2020-10-22 | 2022-11-01 | 山东农业大学 | 具有跨种传播能力的新型鹅星状病毒及其应用 |
| CN112526127B (zh) * | 2020-10-28 | 2022-12-06 | 四川大学华西医院 | 一种破伤风抗原的检测方法及其应用 |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| CN112574997B (zh) * | 2021-01-17 | 2023-07-21 | 楷拓生物科技(苏州)有限公司 | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 |
| CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| JP7894875B2 (ja) * | 2021-02-12 | 2026-07-24 | シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート | 熱ショックタンパク質90結合ドメインを有する活性誘導型融合タンパク質 |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
| CN113341152B (zh) * | 2021-04-27 | 2022-04-26 | 华南农业大学 | Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| EP4377331A2 (en) | 2021-07-30 | 2024-06-05 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| IL309502A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| CN115029349B (zh) * | 2022-06-09 | 2024-11-12 | 中国农业大学 | 与植物抗病性相关的circRNA、来源基因及其应用 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| AU2023310896A1 (en) | 2022-07-19 | 2025-01-30 | Shenzhen Shenxin Biotechnology Co., Ltd. | Mrna for sars-cov-2 s protein and use thereof |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN115606550B (zh) * | 2022-10-28 | 2024-01-12 | 陆华 | 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法 |
| WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| TW202430633A (zh) * | 2022-12-07 | 2024-08-01 | 科羅拉多大學董事會法人團體 | 新穎的hiv-1變異體及其在動物激發模型中的使用方法 |
| US20260209719A1 (en) | 2022-12-16 | 2026-07-23 | Shenzhen Shenxin Biotechnology Co., Ltd. | Utr for improving translation efficiency and/or stability of rna molecule and use thereof |
| IL322426A (en) | 2023-01-31 | 2025-09-01 | Synplogen Co Ltd | Artificial synthetic nucleic acid for enhancing protein expression |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| CN116240175B (zh) * | 2023-02-28 | 2024-02-23 | 武汉科技大学 | 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024188312A1 (en) * | 2023-03-16 | 2024-09-19 | The Hong Kong University Of Science And Technology | Compositions and methods for enhanced protein expression |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| JP2026518411A (ja) | 2023-04-27 | 2026-06-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザウイルスワクチン |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| EP4713483A1 (en) | 2023-05-16 | 2026-03-25 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2025027060A1 (en) * | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025040263A1 (en) | 2023-08-24 | 2025-02-27 | CureVac Manufacturing GmbH | Purification process for in vitro amplified dna |
| JP2025082576A (ja) * | 2023-11-17 | 2025-05-29 | アンジェス株式会社 | 核酸、医薬組成物、及び核酸を製造する方法 |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| CN122180503A (zh) | 2024-04-30 | 2026-06-09 | 深圳深信生物科技有限公司 | 脂质纳米颗粒及其应用 |
| WO2025246436A1 (en) * | 2024-05-29 | 2025-12-04 | Therorna Inc. | Circular rna-based therapeutic vaccine for treating hpv positive cancer |
| WO2026115169A1 (en) * | 2024-11-29 | 2026-06-04 | Corequest Sagl | Gene delivery to cells of vectors comprising crat nucleotidic or aminoacidic sequences |
| CN121800306B (zh) * | 2026-01-21 | 2026-08-11 | 南昌航空大学 | 一种双功能固体酸材料催化六氟磷酸根水解方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015512631A (ja) | 2012-03-27 | 2015-04-30 | キュアバック ゲーエムベーハーCurevac Gmbh | タンパク質又はペプチドの発現を改善するための人工核酸分子 |
| JP2015517803A (ja) | 2012-03-27 | 2015-06-25 | キュアバック ゲーエムベーハーCurevac Gmbh | 5’toputrを含む人工核酸分子 |
| WO2016107877A1 (en) | 2014-12-30 | 2016-07-07 | Curevac Ag | Artificial nucleic acid molecules |
| JP2017502670A (ja) | 2013-12-30 | 2017-01-26 | キュアバック アーゲー | 人工核酸分子 |
| WO2018172556A1 (en) | 2017-03-24 | 2018-09-27 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CA2258125C (en) | 1996-06-14 | 2010-11-23 | Meiji Milk Products Co., Ltd. | T-cell epitope peptides |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7060284B1 (en) | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸 |
| WO2008017517A1 (en) | 2006-08-11 | 2008-02-14 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5721441B2 (ja) | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーCurevac Gmbh | 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体 |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| WO2010087791A1 (en) | 2009-01-27 | 2010-08-05 | Utc Power Corporation | Distributively cooled, integrated water-gas shift reactor and vaporizer |
| EP2391343B1 (en) | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN104922071A (zh) | 2010-04-09 | 2015-09-23 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| PL3019619T3 (pl) * | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
| AU2014310932B2 (en) | 2013-08-21 | 2019-06-06 | CureVac SE | Composition and vaccine for treating lung cancer |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| BR112016000889A2 (pt) | 2013-08-21 | 2017-12-12 | Curevac Ag | composição e vacina para tratamento de câncer de próstata |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| HRP20220070T1 (hr) * | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| EP4239080A3 (en) * | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
| US12258567B2 (en) * | 2015-08-28 | 2025-03-25 | CureVac SE | Artificial nucleic acid molecules |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
| WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
-
2018
- 2018-10-17 BR BR112020004351-6A patent/BR112020004351A2/pt unknown
- 2018-10-17 US US16/757,289 patent/US20220233568A1/en active Pending
- 2018-10-17 IL IL321714A patent/IL321714A/en unknown
- 2018-10-17 KR KR1020257029819A patent/KR20250138817A/ko active Pending
- 2018-10-17 RU RU2020115287A patent/RU2020115287A/ru unknown
- 2018-10-17 MX MX2020003995A patent/MX2020003995A/es unknown
- 2018-10-17 CA CA3073634A patent/CA3073634A1/en active Pending
- 2018-10-17 KR KR1020207012300A patent/KR102858623B1/ko active Active
- 2018-10-17 EP EP18789606.3A patent/EP3697912A1/en active Pending
- 2018-10-17 WO PCT/EP2018/078453 patent/WO2019077001A1/en not_active Ceased
- 2018-10-17 SG SG11202002186VA patent/SG11202002186VA/en unknown
- 2018-10-17 CN CN201880067696.6A patent/CN111630173A/zh active Pending
- 2018-10-17 JP JP2020521986A patent/JP7863957B2/ja active Active
- 2018-10-17 AU AU2018351481A patent/AU2018351481B2/en active Active
-
2020
- 2020-02-23 IL IL272850A patent/IL272850A/en unknown
- 2020-07-13 MX MX2026002469A patent/MX2026002469A/es unknown
-
2023
- 2023-11-06 JP JP2023189376A patent/JP2024012523A/ja active Pending
-
2025
- 2025-02-10 AU AU2025200901A patent/AU2025200901A1/en active Pending
- 2025-05-30 JP JP2025090961A patent/JP2025131658A/ja active Pending
-
2026
- 2026-02-12 JP JP2026021312A patent/JP2026090405A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015512631A (ja) | 2012-03-27 | 2015-04-30 | キュアバック ゲーエムベーハーCurevac Gmbh | タンパク質又はペプチドの発現を改善するための人工核酸分子 |
| JP2015517803A (ja) | 2012-03-27 | 2015-06-25 | キュアバック ゲーエムベーハーCurevac Gmbh | 5’toputrを含む人工核酸分子 |
| JP2017502670A (ja) | 2013-12-30 | 2017-01-26 | キュアバック アーゲー | 人工核酸分子 |
| WO2016107877A1 (en) | 2014-12-30 | 2016-07-07 | Curevac Ag | Artificial nucleic acid molecules |
| WO2018172556A1 (en) | 2017-03-24 | 2018-09-27 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| Molecular Therapy, 2015, Vol.23, No.9, p.1456-1464 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200071081A (ko) | 2020-06-18 |
| JP2026090405A (ja) | 2026-06-02 |
| AU2025200901A1 (en) | 2025-02-27 |
| KR102858623B1 (ko) | 2025-09-10 |
| JP2021501572A (ja) | 2021-01-21 |
| WO2019077001A1 (en) | 2019-04-25 |
| AU2018351481B2 (en) | 2025-04-03 |
| EP3697912A1 (en) | 2020-08-26 |
| IL272850A (en) | 2020-04-30 |
| AU2018351481A1 (en) | 2020-03-12 |
| US20220233568A1 (en) | 2022-07-28 |
| SG11202002186VA (en) | 2020-05-28 |
| KR20250138817A (ko) | 2025-09-22 |
| RU2020115287A (ru) | 2021-11-19 |
| JP2024012523A (ja) | 2024-01-30 |
| CN111630173A (zh) | 2020-09-04 |
| JP2025131658A (ja) | 2025-09-09 |
| RU2020115287A3 (cg-RX-API-DMAC7.html) | 2022-02-28 |
| IL321714A (en) | 2025-08-01 |
| MX2026002469A (es) | 2026-04-01 |
| BR112020004351A2 (pt) | 2020-09-08 |
| MX2020003995A (es) | 2020-07-22 |
| CA3073634A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102858623B1 (ko) | 신규 인공 핵산 분자 | |
| KR101343043B1 (ko) | 포유동물 내 면역자극성 반응 제공 또는 증강을 위한 노출된 mRNA 및 착화된 (m)RNA를 포함하는 조성물 및 이의 용도 | |
| KR101513254B1 (ko) | 트랜스펙션 및 면역자극을 위한 rna 및 양이온성 펩타이드의 복합체 | |
| US9616084B2 (en) | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids | |
| WO2011069587A1 (en) | Lyophilization of nucleic acids in lactate-containing solutions | |
| WO2010088927A1 (en) | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds | |
| EP3424524B1 (en) | Cancer rna-vaccine | |
| EP2510100B1 (en) | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211015 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221011 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230411 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231109 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231129 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260512 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7863957 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |